Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R. Harbeck N, et al. Among authors: hartmann a, hartmann o. J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18. J Clin Oncol. 2008. PMID: 18711169
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Dürst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ. Dahl E, et al. Among authors: hartmann a. Clin Cancer Res. 2006 Jul 1;12(13):3950-60. doi: 10.1158/1078-0432.CCR-05-2090. Clin Cancer Res. 2006. PMID: 16818692
Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.
Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Rody A, Schaefer KL, Baldus SE, Hartmann A, Wild PJ, Burson M, Gabbert HE, Nitz U, Poremba C. Diallo-Danebrock R, et al. Among authors: hartmann a. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):488-97. doi: 10.1158/1078-0432.CCR-06-1842. Clin Cancer Res. 2007. PMID: 17255270 Clinical Trial.
The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E. Veeck J, et al. Among authors: hartmann a. Oncogene. 2008 Jan 31;27(6):865-76. doi: 10.1038/sj.onc.1210669. Epub 2007 Jul 23. Oncogene. 2008. PMID: 17653090
3,471 results